Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1995-7-6
|
pubmed:abstractText |
Chromogranin A (CgA) is the major member of the granin family of acidic secretory glycoproteins that are expressed in all endocrine and neuroendocrine cells. Granins have been proposed to play multiple roles in the secretory process. Intracellularly, granins play a role in targeting peptide hormones and neurotransmitters to granules of the regulated pathway by virtue of their ability to aggregate in the low-pH, high-calcium environment of the trans-Golgi network. Extra-cellularly, peptides formed as a result of proteolytic processing of granins regulate hormone secretion. Some conserved features of the mature CgA protein are polyglutamic acids, calcium-binding sites, and several pairs of basic amino acids. The first 2 features are important for its intracellular functions, and the latter characteristic suggested that peptides could be released from the molecule by precursor processing enzymes. Several biologically active peptides encoded within the CgA molecule, such as vasostatin, beta-granin, chromostatin, pancreastatin, and parastatin act predominantly to inhibit hormone and neurotransmitter release in an autocrine or paracrine fashion. The biosynthesis of CgA is regulated by many different factors, including steroid hormones and agents that act through a variety of signalling pathways. CgA biosynthesis and that of the resident hormone or neurotransmitter can be regulated differentially. The widespread distribution of CgA has made the measurement of circulating immunoreactive CgA a valuable tool in the diagnosis of neuroendocrine neoplasia, and CgA immunohistochemistry can help to identify the neuroendocrine nature of tumours. Recent molecular biology studies are identifying those elements in the CgA gene promoter responsible for its specific neuroendocrine cell expression.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0147-958X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
18
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
47-65
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:7768066-Animals,
pubmed-meshheading:7768066-Biological Evolution,
pubmed-meshheading:7768066-Chromogranin A,
pubmed-meshheading:7768066-Chromogranins,
pubmed-meshheading:7768066-Endocrine Glands,
pubmed-meshheading:7768066-Gene Expression,
pubmed-meshheading:7768066-Humans,
pubmed-meshheading:7768066-Neuroendocrine Tumors,
pubmed-meshheading:7768066-Neurosecretory Systems,
pubmed-meshheading:7768066-Signal Transduction,
pubmed-meshheading:7768066-Tumor Markers, Biological
|
pubmed:year |
1995
|
pubmed:articleTitle |
Chromogranin A.
|
pubmed:affiliation |
Calcium Research Laboratory, McGill University, Montreal, Quebec.
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|